Data on migration of the non-invasive breast cancer cell line, MCF-7 treated with Bevacizumab using Real Time Cell Analyzer (RTCA)

Layal El-Hajjar; Abdullah Shaito; Nour Jalaleddine; Kazem Zibara; Jalal M Kazan; Jamal El-Saghir; Marwan El-Sabban

doi:10.1016/j.dib.2018.12.059

Data on migration of the non-invasive breast cancer cell line, MCF-7 treated with Bevacizumab using Real Time Cell Analyzer (RTCA)

Data Brief. 2018 Dec 21:22:635-638. doi: 10.1016/j.dib.2018.12.059. eCollection 2019 Feb.

Authors

Layal El-Hajjar¹, Abdullah Shaito¹, Nour Jalaleddine², Kazem Zibara³, Jalal M Kazan⁴, Jamal El-Saghir⁴, Marwan El-Sabban⁴

Affiliations

¹ Department of Biological and Environmental Sciences, Faculty of Science, Beirut Arab University, Beirut, Lebanon.
² Department of Biological and Chemical Sciences, Faculty of Arts and Sciences, Lebanese International University, Beirut, Lebanon.
³ ER045 - Laboratory of Stem Cells, PRASE, Biology Department, Faculty of Sciences, Lebanese University, Beirut, Lebanon.
⁴ Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

Abstract

Bevacizumab or Avastin® (Av), the recombinant antibody targeting VEGF, improves progression-free but not overall survival of metastatic breast cancer patients due to development of Av resistance. We showed that Av-therapy-induced inflammatory microenvironment contributes to the refractoriness to Av treatment. Here we present data regarding the effect of Av treatment on migration of a non-invasive breast cancer cell line, MCF-7. The data presented hereis related to the research article "Bevacizumab induces inflammation in MDA-MB-231 breast cancer cell line and in a mouse model" (Hajjar et al., 2018).

Keywords: Bevacizumab; MCF-7; Migration; RTCA.